Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study.
Walters TR, Kothe AC, Boyer JL, Usner DW, Lopez K, Duquesroix B, Fechtner RD, Navratil T. Walters TR, et al. Among authors: navratil t. J Glaucoma. 2022 Jun 1;31(6):382-391. doi: 10.1097/IJG.0000000000002030. Epub 2022 Apr 6. J Glaucoma. 2022. PMID: 35394456 Free PMC article. Clinical Trial.
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Berdahl JP, Sarkisian SR Jr, Ang RE, Doan LV, Kothe AC, Usner DW, Katz LJ, Navratil T; Travoprost Intraocular Implant Study Group. Berdahl JP, et al. Among authors: navratil t. Drugs. 2024 Jan;84(1):83-97. doi: 10.1007/s40265-023-01973-7. Epub 2023 Dec 7. Drugs. 2024. PMID: 38060092 Free PMC article. Clinical Trial.
Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial.
Sarkisian SR, Ang RE, Lee AM, Berdahl JP, Heersink SB, Burden JH, Doan LV, Stephens KG, Applegate D, Kothe AC, Usner DW, Katz LJ, Navratil T. Sarkisian SR, et al. Among authors: navratil t. Ophthalmol Ther. 2024 Apr;13(4):995-1014. doi: 10.1007/s40123-024-00898-y. Epub 2024 Feb 12. Ophthalmol Ther. 2024. PMID: 38345710 Free PMC article.
Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Sarkisian SR Jr, Ang RE, Lee AM, Berdahl JP, Heersink SB, Burden JH, Doan LV, Stephens KG, Kothe AC, Usner DW, Katz LJ, Navratil T; GC-010 Travoprost Intraocular Implant Investigators. Sarkisian SR Jr, et al. Among authors: navratil t. Ophthalmology. 2024 Sep;131(9):1021-1032. doi: 10.1016/j.ophtha.2024.02.022. Epub 2024 Feb 27. Ophthalmology. 2024. PMID: 38423216 Clinical Trial.
NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
Bastia E, Toris C, Bukowski JM, Brambilla S, Galli C, Almirante N, Bergamini MVW, Lucarini L, Navratil T, Impagnatiello F. Bastia E, et al. Among authors: navratil t. J Ocul Pharmacol Ther. 2021 May;37(4):215-222. doi: 10.1089/jop.2020.0126. Epub 2021 Feb 15. J Ocul Pharmacol Ther. 2021. PMID: 33595367
NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs.
Bastia E, Toris CB, Brambilla S, Galli C, Almirante N, Bergamini MVW, Masini E, Sgambellone S, Unser AM, Ahmed F, Torrejon KY, Navratil T, Impagnatiello F. Bastia E, et al. Among authors: navratil t. Invest Ophthalmol Vis Sci. 2021 Mar 1;62(3):17. doi: 10.1167/iovs.62.3.17. Invest Ophthalmol Vis Sci. 2021. PMID: 33704360 Free PMC article.
121 results